EA201691691A1 - Белки слияния tatk-cdkl5, их композиции, составы и применение - Google Patents

Белки слияния tatk-cdkl5, их композиции, составы и применение

Info

Publication number
EA201691691A1
EA201691691A1 EA201691691A EA201691691A EA201691691A1 EA 201691691 A1 EA201691691 A1 EA 201691691A1 EA 201691691 A EA201691691 A EA 201691691A EA 201691691 A EA201691691 A EA 201691691A EA 201691691 A1 EA201691691 A1 EA 201691691A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tatk
compositions
cdkl5
proteins
applications
Prior art date
Application number
EA201691691A
Other languages
English (en)
Other versions
EA038000B1 (ru
Inventor
Элизабетта Чани
Франко Лакконе
Original Assignee
Альма Матер Студиорум-Юниверсита Ди Болонья
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Альма Матер Студиорум-Юниверсита Ди Болонья filed Critical Альма Матер Студиорум-Юниверсита Ди Болонья
Publication of EA201691691A1 publication Critical patent/EA201691691A1/ru
Publication of EA038000B1 publication Critical patent/EA038000B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

В данном документе раскрыты композиции и составы, содержащие белок слияния TATk-CDKL5. Также раскрыты способы получения белка слияния TATk-CDKL5 с помощью векторов, содержащих кДНК TATk-CDKL5, и способы трансдукции клеток векторами, содержащими кДНК TATk-CDKL5, и белком слияния TATk-CDKL5.
EA201691691A 2014-02-28 2015-02-27 Слитый белок для лечения одного или нескольких симптомов дефицита cdkl5 и его применение EA038000B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28
PCT/IB2015/000999 WO2015128746A2 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Publications (2)

Publication Number Publication Date
EA201691691A1 true EA201691691A1 (ru) 2017-05-31
EA038000B1 EA038000B1 (ru) 2021-06-22

Family

ID=53539745

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202190727A EA202190727A3 (ru) 2014-02-28 2015-02-27 Рекомбинантная нуклеиновая кислота, вектор, содержащий ее, и способ, предусматривающий трансфекцию клеток
EA201691691A EA038000B1 (ru) 2014-02-28 2015-02-27 Слитый белок для лечения одного или нескольких симптомов дефицита cdkl5 и его применение

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202190727A EA202190727A3 (ru) 2014-02-28 2015-02-27 Рекомбинантная нуклеиновая кислота, вектор, содержащий ее, и способ, предусматривающий трансфекцию клеток

Country Status (32)

Country Link
US (4) US9290746B2 (ru)
EP (2) EP3110837B1 (ru)
JP (2) JP6629747B2 (ru)
KR (1) KR102307276B1 (ru)
CN (1) CN106255706A (ru)
AU (2) AU2015221860B2 (ru)
BR (1) BR112016019868B1 (ru)
CA (1) CA2940401C (ru)
CL (1) CL2016002142A1 (ru)
CR (1) CR20160392A (ru)
CY (2) CY1122644T1 (ru)
DK (2) DK3110837T3 (ru)
DO (1) DOP2016000220A (ru)
EA (2) EA202190727A3 (ru)
ES (2) ES2745335T3 (ru)
HR (2) HRP20191511T1 (ru)
HU (2) HUE045393T2 (ru)
IL (2) IL247481B (ru)
LT (2) LT3608334T (ru)
MX (2) MX2016011167A (ru)
MY (1) MY181566A (ru)
NI (1) NI201600127A (ru)
PE (1) PE20161406A1 (ru)
PH (1) PH12016501689A1 (ru)
PL (2) PL3110837T3 (ru)
PT (2) PT3608334T (ru)
RS (2) RS62244B1 (ru)
SG (2) SG10202000537RA (ru)
SI (2) SI3608334T1 (ru)
SV (1) SV2016005264A (ru)
WO (1) WO2015128746A2 (ru)
ZA (2) ZA201606655B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3608334T (pt) * 2014-02-28 2021-08-25 Alma Mater Studiorum Univ Bologna Proteínas de fusão tatk-cdkl5, composições, formulações e utilização das mesmas
JP2019522989A (ja) * 2016-06-28 2019-08-22 アルマ マータ ステューディオラム — ユニバーシタ ディ ボローニャ ＴＡＴκ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用
CA3083951A1 (en) * 2017-11-30 2019-06-06 Amicus Therapeutics, Inc. Cdkl5 expression variants and cdkl5 fusion proteins
US11058725B2 (en) 2019-09-10 2021-07-13 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
JP2022554267A (ja) * 2019-10-30 2022-12-28 アミカス セラピューティックス インコーポレイテッド 組換えｃｄｋｌ５タンパク質、遺伝子療法、及び製造方法
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
US20230414785A1 (en) 2020-12-01 2023-12-28 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG189519A1 (en) * 2010-10-25 2013-05-31 Univ D Axi Marseille TREATMENT OF MeCP2-ASSOCIATED DISORDERS
PT3608334T (pt) * 2014-02-28 2021-08-25 Alma Mater Studiorum Univ Bologna Proteínas de fusão tatk-cdkl5, composições, formulações e utilização das mesmas

Also Published As

Publication number Publication date
HUE045393T2 (hu) 2019-12-30
CL2016002142A1 (es) 2017-09-08
US9944910B2 (en) 2018-04-17
HRP20191511T1 (hr) 2019-11-29
ES2745335T3 (es) 2020-02-28
PE20161406A1 (es) 2017-01-14
PH12016501689B1 (en) 2016-10-03
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
NI201600127A (es) 2017-03-13
DOP2016000220A (es) 2016-12-15
US20200199549A1 (en) 2020-06-25
AU2015221860B2 (en) 2019-09-12
US10584318B2 (en) 2020-03-10
US10907138B2 (en) 2021-02-02
AU2019219743B2 (en) 2020-10-29
CA2940401A1 (en) 2015-09-03
BR112016019868A2 (pt) 2017-10-17
SI3608334T1 (sl) 2021-11-30
EP3608334A1 (en) 2020-02-12
LT3110837T (lt) 2019-10-10
JP6896050B2 (ja) 2021-06-30
EP3608334B1 (en) 2021-05-19
RS62244B1 (sr) 2021-09-30
MX2016011167A (es) 2017-04-06
SV2016005264A (es) 2017-02-15
IL275435B (en) 2021-07-29
CY1122644T1 (el) 2021-03-12
PL3608334T3 (pl) 2021-11-22
SG11201606863YA (en) 2016-09-29
ZA201606655B (en) 2020-05-27
WO2015128746A3 (en) 2015-11-26
KR102307276B1 (ko) 2021-09-30
IL275435A (en) 2020-08-31
CN106255706A (zh) 2016-12-21
SI3110837T1 (sl) 2019-12-31
ZA201906304B (en) 2022-03-30
AU2015221860A1 (en) 2016-09-08
HRP20211324T1 (hr) 2021-11-26
EP3110837A2 (en) 2017-01-04
RS59344B1 (sr) 2019-10-31
US20150247134A1 (en) 2015-09-03
EA202190727A2 (ru) 2021-07-30
JP2017507655A (ja) 2017-03-23
US9290746B2 (en) 2016-03-22
IL247481A0 (en) 2016-11-30
WO2015128746A2 (en) 2015-09-03
EA202190727A3 (ru) 2021-11-30
IL247481B (en) 2020-07-30
PT3608334T (pt) 2021-08-25
DK3110837T3 (da) 2019-09-16
CY1124727T1 (el) 2022-07-22
CA2940401C (en) 2022-11-29
MX2020001223A (es) 2022-05-31
KR20170002372A (ko) 2017-01-06
AU2019219743A1 (en) 2019-09-19
PT3110837T (pt) 2019-09-12
PH12016501689A1 (en) 2016-10-03
DK3608334T3 (da) 2021-08-23
NZ723371A (en) 2023-11-24
HUE055282T2 (hu) 2021-11-29
PL3110837T3 (pl) 2020-04-30
US20180327725A1 (en) 2018-11-15
US20160194617A1 (en) 2016-07-07
EP3110837B1 (en) 2019-06-12
BR112016019868B1 (pt) 2023-11-28
JP6629747B2 (ja) 2020-01-15
EA038000B1 (ru) 2021-06-22
JP2020062022A (ja) 2020-04-23
SG10202000537RA (en) 2020-03-30
CR20160392A (es) 2017-06-12
ES2885245T3 (es) 2021-12-13

Similar Documents

Publication Publication Date Title
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
EA201890423A1 (ru) Слитые белки фактора ix, способы их получения и применения
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
BR112019012343A2 (pt) anticorpos il-11ra
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MY198059A (en) Anti-ox40 antibodies and their uses
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA201791500A1 (ru) Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
PH12017502277A1 (en) Multi-specific binding proteins
NZ746677A (en) Novel alpha-1-microglobulin derived proteins and their use
EA201991768A1 (ru) Слитые белки на основе фактора ix и способы их получения и пути применения
EA202092327A1 (ru) Варианты lfa3 и их композиции и применение
EA201990927A1 (ru) Антитела против lag-3 и способы их применения
BR112017010627A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças